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The current therapeutic options available for the treatment of
patients with metastatic melanoma remain ineffective. Similarly,
the search for new effective agents has not been successful identi-
fying interesting compounds. Given the above, the search for
successful adjuvant therapy for patients with high-risk melanoma
has been hampered.
We and others have completed a number of studies employing
what is referred to as the Dartmouth regimen, in the treatment of
patients with metastatic disease (McClay et al, 1987, 1988, 1992b,
1993c; Richards et al, 1992; Saba et al, 1992; DelPrete et al, 1993;
Lattanzi et al, 1993; Creagan et al, 1999; Saxman et al, 1999). To
date, in 862 patients reported in the medical literature, treated with
this regimen, the overall response rate is 31.8% (95% confidence
limits 28.44–34.66%) with a complete response (CR) rate of 10%.
These studies suggest a modest improvement in the overall and
complete response rate with no statistically significant effect on
DFS or OS. In the laboratory, we have identified a previously
unrecognized synergistic cytotoxic interaction between TAM and
DDP that may be the basis for the improved results observed with
this regimen (McClay et al, 1992a, 1993a, 1993b, 1994). Based
upon these clinical and laboratory data and the hypothesis that, if a
clinically important synergistic interaction exists between TAM
and DDP, then benefit would be most likely observed in the adju-
vant setting, we began a phase II study of the combination of TAM
and DDP in high-risk melanoma patients.
PATIENTS AND METHODS
Patient selection
In 1993, we began this phase II trial in cooperation with physicians
in the primarily southeastern United States. A total of 39 commu-
nity- and university-based physicians from the states of South
Carolina, Georgia, North Carolina, Florida and Texas participated
and treated patients on this programme. Patients eligible for this
programme were required to have histologically documented
malignant melanoma. Stage was determined by the use of the
American Joint Commission on Cancer (AJCC) melanoma staging
criteria. Selection factors for high-risk included those stage II
patients who had a predicted risk of recurrence of at least 40% as
determined by the tables of Clark et al (1989), as well as stage III
and IV patients who could be rendered disease-free by surgical
intervention. All pathologic slide review and interpretation of
Clark’s prognostic factors were conducted by one or both of the
dermatopathologists (JSM, JCM) on the panel. Patients were
required to have an ECOG performance status of 0–1 with normal
renal, hepatic and haematologic function. Computerized tomo-
grams (CT) of the chest, abdomen and pelvis without evidence of
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metastatic disease were required to be done within 1 month of the
initiation of treatment. After informed consent, patients were
started on treatment.
Treatment
The treatment regimen included TAM 160 mg day–1 on days 1–7
and DDP 100 mg m–2 on day 2. DDP treatment was given in
association with aggressive intravenous (i.v.) hydration and
prophylactic anti-emetics. The anti-emetic regimen consisted of
dexamethasone 20 mg i.v. in combination with either ondansetron
(32 mg i.v.) or granisetron (10 mg kg–1). Post-treatment prophyl-
actic anti-emetics typically included metaclopromide (10 mg
orally four times a day ´ 5 days) and ondansetron (8 mg orally
twice a day ´ 5 days). The patients received a total of 4 cycles
repeated at 28-day intervals.
Evaluation
Following treatment, the patients were evaluated every 2 months
for the first 2 years with a history and physical exam as well as
laboratory monitoring. Similarly, CT scans of the chest, abdomen
and pelvis were done every 4 months for the first 2 years.
Thereafter the patients were evaluated by history, physical exam
and laboratory measures only. The development of new symptoms
prompted immediate radiographic investigation. The National
Cancer Institute’s New Common Toxicity Grading System was
employed to grade all toxicity on this trial.
Statistical measures
The disease-free survival (DFS) and overall survival (OS) were
measured from the date of surgical intervention until recurrence of
disease or death. The Kaplan–Meier method of survival analysis
was employed to determine both DFS and OS (Kaplan and Meier
1958). The Mantel–Cox log-rank test was employed to determine
statistical significance.
RESULTS
Patient characteristics
A total of 153 patients were entered onto this study, 92 males and
61 females with a median age of 51 years (range 19–78) (Table 1).
All patients registered for the study are reported in this manuscript.
All patients had an ECOG performance status of 0 with normal
renal, hepatic and haematologic function. The number of patients
at each stage of disease at entry onto the study was as follows:
stage IIb – 64; stage III – 74; stage IV – 15 (Table 1). The median
risk of recurrence for the stage IIb patients as predicted by the
Clark’s tables was 70% (Clark et al, 1989). This level of risk corre-
sponds to that associated with a Breslow’s depth of invasion of 
> 5 mm, if only depth is used to determine the risk of recurrence.
Sites of disease for the stage IV patients prior to surgical resection
included: skin (11), lung (2), brain (1), lymph nodes (3) and
gastrointestinal (GI) (1).
Survival
The median follow-up time for patients on this study 36 months.
At the present time, the median DFS and OS have not yet been
reached. The DFS is 68.4% while the OS is 84.5%. Kaplan–Meier
analysis projected a 5-year DSF of 62% while the projected 5-year
OS is 79% (Figures 1 and 2).
Cocconi et al (1992) reported a potential survival advantage for
females treated on their programme which included TAM and
DTIC. For this reason, we investigated the effect of gender on
survival for our patient population. As can be seen in Figures 3 and
4, gender had no effect on either the DFS or OS in this trial.
It is well established that the number of lymph nodes that
contain metastatic melanoma at diagnosis adversely effects the
survival of patients with stage III disease. We investigated this
effect in our patient population. We were unable to confirm an
adverse effect on survival (Figures 5 and 6). However, the stage of
disease of the patient prior to surgery did effect both the DFS and
Table 1 Patient characteristics
Males Females Total
No. of patients 92 61 153
Stage IIb 46 18 64
Stage III 42 32 74
Stage IV 4 11 15
ECOG PS 0 92 61 153
Age: median, 50.9; range, 19–78.
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Figure 1 Disease-free survival for all patients in comparison to the results
of the ECOG 1684 Study
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Figure 2 Overall survival for all patients in comparison to the results of the
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OS experienced by patients treated on this programme (Figures 7
and 8). Those patients with stage IV disease prior to surgery had a
statistically significant poorer DFS and OS in comparison to the
stage II and III patients.
Toxicity
Of the 153 patients treated on this regimen, 127 (83%) received all
four planned treatments. Of the 26 (17%) who failed to complete
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Figure 3 Effect of gender on disease-free survival
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Figure 4 Effect of gender on overall survival
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Figure 5 Effect of lymph node status on disease-free survival
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the programme, nine failed to do so because of the development of
metastatic disease while on treatment while the others discon-
tinued treatment due to toxicity. For the most part, persistent
nausea with or without emesis was the most difficult symptom to
treat (Table 2). Despite the use of prophylactic anti-emetics,
nausea and emesis remained a significant problem for a majority
of patients. Approximately 75% of all patients experienced grade
II or higher nausea and/or emesis. While our numbers are too
small to be significant, this problem appeared to be most signifi-
cant in young women. In general, patients older than 60 years of
age tolerated this regimen better from a GI standpoint than did the
younger patients.
Only one patient developed grade II renal toxicity. This
occurred in a patient with type II diabetes mellitus. Otherwise,
minor elevations of the serum creatinine were observed in 32 addi-
tional patients, all of which returned to normal prior to the next
treatment cycle. Further cycles were given with a 25% dose reduc-
tion of the DDP.
No significant haematologic, neurotoxicity or ototoxicity was
encountered.
DISCUSSION
Adjuvant therapy for patients with malignant melanoma has
suffered from a lack of therapeutic agents that have activity in
treating this disease. Despite this fact, a number of treatments have
been evaluated in this setting, ranging from non-specific immune
system stimulating agents to combination chemotherapy
(Kirkwood et al, 1998). Levamisole, an antihelmintic agent with a
variety of non-specific immune system effects was evaluated in
several adjuvant melanoma studies, without clear success (Quirt et
al, 1991; Spitler, 1991). Similarly, bacille Calmette-Guérin (BCG)
has not been shown to effect either the DFS or OS (Czarnetzki
et al, 1993).
The use of systemic chemotherapy has also not proved to be of
benefit. Single-agent dacarbazine failed to improve the survival of
high-risk stage I patients when compared with levamisole or
placebo (Lejeune et al, 1988). Retsas et al (1995) have compared
the survival of 87 stage III patients treated with adjuvant vindesine
with the survival of 82 untreated patients in a non-randomized
study. In contrast to other studies, the authors demonstrated a
modest benefit in both DFS and OS in favour of the treated group.
Not unexpectedly, combination chemotherapy has faired no better
than other approaches (Pectasides et al, 1994).
Many recent studies have focused on the use of interferon (IFN)
in the adjuvant setting with mixed results (Cascinelli et al, 1994;
Creagan et al, 1995; Cole et al, 1996; Kirkwood et al, 1996;
Pehamberger et al, 1998). To date only one study (ECOG 1684)
has demonstrated a survival advantage for the use of high-dose
IFN-a-2b (Kirkwood et al, 1996). This result was not confirmed in
the yet to be published follow-up study (ECOG 1690) which found
no survival advantage with the use of IFN-a-2b (http://
cancertrials.nci.nih.gov/NCI_CANCER_TRIALS).
Our choice of the combination TAM and DDP stems from our
clinical work with the Dartmouth regimen which suggests that
TAM can overcome DDP resistance in selected patients with
melanoma (McClay et al, 1987, 1989, 1992b, 1993c). In the early
1990s, in an attempt to determine the mechanism of action that
might explain why this regimen might be effective, we began both
clinical as well as laboratory investigations. We hypothesized that
a previously unrecognized interaction between TAM and DDP
was responsible for our observations. We subsequently conducted
a clinical trial with this combination in previously untreated
patients (McClay et al, 1993c). Patients were initially treated with
DDP alone and, upon failure, subsequently treated with the combi-
nation of TAM/DDP. We observed a 33% response rate in patients
treated with the combination after failure with single-agent DDP.
While the clinical response of the patients was short lived, we
believe that this response represented a biologically important
observation, suggesting that clinical resistance to DDP could be
overcome with high-dose TAM.
In the laboratory, we have confirmed the presence of a previ-
ously unrecognized synergistic cytotoxic interaction between
TAM and DDP which may be the basis for the modest improve-
ment in results that have been reported in several of the above
studies (McClay et al, 1992a, 1993a, 1993b, 1994). In these exper-
iments, TAM was able to make DDP-sensitive melanoma cells
more sensitive and DDP-resistant cells, sensitive. Of interest,
however, our in vitro data suggested that higher concentrations of
TAM would be required to overcome DDP resistance (McClay
et al, 1993a).
Based upon the above clinical and laboratory data and the ratio-
nale that the adjuvant setting provides the best opportunity to
determine an effect of a treatment regimen on survival, we began
this phase II pilot trial in 1993. Thirty-eight physicians, primarily
from the south and southeastern United States, participated in the
conduct of this trial. Melanoma was histologically confirmed and
the risk of recurrence determined after review of the pathology
slides by our reference dermatopathologists.
With a median follow-up time of 36 months, the median DFS
and OS have not yet been reached. At present, the DFS is 68.4%
and the OS is 84.5%. Kaplan–Meier analysis predicts a 5-year
DFS of 62% with a 5-year OS of 79%. Relapses after 20 months
have been rare and the survival curves appear to plateau after
25–30 months (Figures 1 and 2).
While others have suggested a survival advantage for female
patients treated with TAM-containing regimens, we were unable to
confirm this result (Cocconi et al, 1992). There was no statistically
significant advantage observed for women treated with this
regimen. Similarly, while there was a trend of worsening outcome
(both DFS and OS) with an increasing number of positive lymph
nodes at study entry, the trend did not reach statistical significance
(P = 0.26).
In contrast, the stage of the patient at entry onto the trial did
have a statistically significant effect on both DFS and OS. Those
patients with stage IV disease prior to surgical intervention, had a
poorer outcome as measured by both DFS and OS. Despite this,
several of these patients have enjoyed clinically meaningful
benefit in both DFS and OS.
Table 2 Toxicity
Tox/Grade 0 I II III IV
Renal 120 32 1 0 0
Nausea 3 37 70 43 –
Emesis 24 10 86 0 33
Neut/ Throm 151 2 0 0 0
Anaemia 120 33 0 0 0
Neuro 148 5 0 0 0
Ototoxicity 151 2 0 0 0
DVT/PE 2/120 EF McClay et al
British Journal of Cancer (2000) 83(1), 16–21 © 2000 Cancer Research Campaign
This programme was reasonably well tolerated except for
nausea and emesis. These symptoms were most common in
patients who were younger than 60 years of age, especially young
women. The reasons for this are unclear but may be related to the
high doses of TAM employed in this regimen. Other significant
toxicities were a rare occurrence. Two patients developed deep
vein thrombosis, one of whom also suffered uncomplicated
pulmonary emboli. This patient presented with a swollen leg and
intermittent cough associated with mild dyspnoea following his
last cycle of therapy. Multiple pulmonary emboli were found on
ventilation/perfusion scan. The patient responded to anticoagula-
tion without further symptoms.
How can we explain our results in light of the studies
(Rusthoven et al, 1996) that have failed to clearly demonstrate a
role for TAM in patients with metastatic disease? The key may be
in the results of the in vitro studies using the combination of
TAM/DDP in DDP-resistant cells (McClay et al, 1994). From a
clinical perspective, most patients with metastatic melanoma are
resistant to DDP. The overall response rate to single-agent DDP is
in the range of 10–20% (Anderson et al, 1995). It follows therefore
that, in the clinical setting, the majority of patients have melanoma
cells that are de novo resistant to DDP. Assuming this is true, our
in vitro data suggest that we should employ a higher dose of TAM
when treating patients. This is the basis for the high dose of TAM
that we have employed in this study. Other randomized and non-
randomized studies have used a standard dose of TAM (20 mg
day–1).
A second obvious point is the fact that patients treated in the
adjuvant setting have fewer malignant cells present than patients
with measurable tumours. Thus, there is less risk that cells resis-
tant to a particular therapy might be present in the patient. This
was the basis for evaluating this combination in the adjuvant
setting.
In summary, our data demonstrate that the use of the combina-
tion of TAM and DDP in high-risk melanoma patients results in an
improvement in both DFS and OS in comparison to IFN-treated or
untreated historical controls. It is stressed that these data are
preliminary in nature and represent the first attempt employing this
approach. We believe that these data support the conduct of a
prospective randomized trial employing the combination of high-
dose TAM and DDP to determine the effect of the combination on
DFS and OS of patients with high-risk melanoma. This type of
study can best be accomplished in the setting of a melanoma
interest group or one of the national cooperative study groups.
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